TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04282031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily on Days 1 to 21 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
Study: NCT01358877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study: NCT03274258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04282031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg once daily of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily of a 28-day cycle
Study: NCT03678753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT03589339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTXR3
Description: Single intra Tumoral injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Radiotherapy given as a definite number of fractions at the dose defined for each radiation field

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monotherapy
Study: NCT01717131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for standard axillary node dissection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No axillary lymph node dissection
Description: No surgery on axillary lymph node
Study: NCT03814200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Single i.v. infusion of 100 mL saline 0.9% for 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475
Description: Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475
Description: Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
Study: NCT03169426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta Blockers Carvedilol Phosphate
Description: Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
Study: NCT02998723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Booster Teaching
Description: The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Booster Teaching
Description: The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
Study: NCT01417845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise Training
Description: * High intensity resistance and aerobic training~* Resistance training is performed 2 days per week for 3 months~* Aerobic training is performed on the same days as resistance training and 1 additional day per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Exercise Training
Description: * Moderate intensity resistance and aerobic training~* Resistance training is performed on 2 days per week for 3 months.~* Aerobic training is performed on the same days as resistance training and 1 additional day per week.
Study: NCT00939692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study: NCT03648632

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
Study: NCT03983395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 250 ng/kg
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
Study: NCT01466829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid hormone
Description: 100 microgram daily. S.c
Study: NCT03983395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 escalating doses,1200 ng/kg D15,22
Description: ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1302 at the MTD and/or RP2D dose
Description: ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
Study: NCT01385735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 Tbl per day, 12 week (84 days) duration
Study: NCT02516670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03942432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Blood samples at T0, T30min, T120min
Study: NCT01466829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; saline injection.
Study: NCT00692536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NNR (Nordic Nutrition Recommendations)
Description: Diet with equal amounts of fat, protein and carbohydrates
Study: NCT04281485

Intervention type: GENETIC
Group type: OTHER
Intervention: PF-06939926
Description: PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
Study: NCT00692536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MPD (Modified paleolithic diet)
Description: A diet high in protein and fat, but low in carbohydrates
Study: NCT01450852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
Study: NCT03942432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: weight, length, waist measurement, cardiac frequency, blood pressure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 Tesla abdominal MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Measurement of body composition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life, physical activity, alcohol consumption and eating habits
Study: NCT03417271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
Study: NCT01150084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16-week lunchtime walking intervention
Description: 10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking

Intervention type: OTHER
Group type: OTHER
Intervention: delayed treatment
Description: to start at week 10
Study: NCT01583179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: added to nerve block, 0.3mg one time peripheral block use
Study: NCT02716012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration
Study: NCT01718184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: toric intraocular lens implantation
Description: piggyback Sulcolflex toric intraocular lens implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sulcoflex intraocular lens implantation
Study: NCT04281485

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.

Intervention type: GENETIC
Group type: OTHER
Intervention: PF-06939926
Description: PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
Study: NCT00264004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: 30 mg \& 45 mg oral tablet
Study: NCT03085719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation is used to shrink the cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation is used to shrink the cancer
Study: NCT03881098

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopies
Description: Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sputum Sample
Description: Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
Study: NCT00898222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 81 mg orally daily for two weeks
Study: NCT06311383

Intervention type: DRUG
Intervention: First-line Ribociclib + endocrine therapy
Description: Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant

Intervention type: DRUG
Intervention: First-line endocrine therapy
Description: As of physicians choice

Intervention type: DRUG
Intervention: First-line chemtherapy
Description: As of physicians choice
Study: NCT01528787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.01%
Description: Administered to study eye, once daily (QD) in the morning (AM) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to study eye, QD AM for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.04%
Description: Administered to study eye, QD AM for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AR-13324 Ophthalmic Solution Vehicle
Description: Administered to study eye, QD AM for 7 days
Study: NCT04047901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Patients undergo 16 weeks of physical training
Study: NCT03592160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
Study: NCT02700178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
Study: NCT04259853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Revascularization on non culprit vessel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Revascularization on non culprit vessel
Study: NCT05328570

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
Study: NCT00372879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 800IU bid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 800IU bid
Study: NCT01356004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: live attenuated chicken pox vaccine
Description: Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline, efficacy
Description: 4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
Study: NCT02697942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: The investigators will provide participants with tablets to play brain games through Lumosity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: The investigators will provide participants with foot peddlers.
Study: NCT04627909

Intervention type: OTHER
Intervention: Robot
Description: The patient interacts with a robot
Study: NCT02716012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200mg
Description: Sorafenib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200mg
Description: Sorafenib tablets
Study: NCT03438370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three monthly ART supply at CAGs
Description: Sites where three monthly ART supply will be provided at outreaches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six monthly ART supply at outreaches
Description: Sites where six monthly ART will supply will be provided at outreaches
Study: NCT00983008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protected time and Dedicated time
Description: On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
Study: NCT04627909

Intervention type: OTHER
Intervention: Medical Personnel
Description: The patient interacts with medical personnel

Intervention type: OTHER
Intervention: Caregiver
Description: The patient interacts with the caregiver